23-NHL-31-CB-PMC: CB-10A, A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Grants and Contracts Details

StatusActive
Effective start/end date9/8/239/8/25

Funding

  • Caribou Biosciences Incorporated: $75,265.00